<DOC>
	<DOCNO>NCT02798393</DOCNO>
	<brief_summary>This double blind , randomize , placebo-controlled study total 120 patient select broad spectrum group typical Americans ( demographic include various race gender well age 25-90 ) confirm Type 2 Diabetes Mellitus suffer mild moderate low extremity Peripheral Neuropathy . All patient meet inclusion and/or exclusion criterion .</brief_summary>
	<brief_title>Efficacy Near Infrared Phototherapy Type 2 Diabetic Neuropathy</brief_title>
	<detailed_description>This double blind , randomize , placebo-controlled study total 120 patient select broad spectrum group typical Americans ( demographic include various race gender well age 25-90 ) confirm Type 2 Diabetes Mellitus suffer mild moderate low extremity Peripheral Neuropathy . All patient meet inclusion and/or exclusion criterion . Randomization Application HL Device The placebo control group 60 patient randomize group 120 patient one designee select placebo v treatment group base acceptable statistical standard determine placebo vs treatment arm research study . There two different HL Devices . There HL-NIR device include NIR diode perform Near Infrared therapy identical appear second device , HL-SHAM device , use placebo device although appearance identical , device perform Near Infrared treatment . Both placebo group treatment group subject NIR sham device apply low extremity short duration three time week course several week .</detailed_description>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>1 . Diagnosis Type 2 Diabetes Mellitus oral hypoglycemic medication , and/or injectable insulin 2 . Hg A1C 5.7 ( ( PreDiabetes 5.7 6.4 % ) ( Diabetes 6.5 % ) ) , Hg A1C 9.1 3 . Peripheral Neuropathy foot , foot legs 4 . If patient low extremity ulceration show sign infection , patient ABPI TBPI 55 mm Hg , may include study , discretion Principal Investigator ( PI ) . If patient infection localize ( osseous nature ) infection treat clear remain uninfected 30 day , patient could reevaluate include study discretion PI . 5 . If patient area injury erythema induration , may still include study ABPI TBPI 55 mm Hg , discretion PI 6 . Positive MNS 7 . All medication treatment neuropathy hold constant least 30 day prior study , baseline treatment period study . 8 . Subjects pain insensate site foot ( foot assess pain scale extremity measured/followed ) . 9 . Moderately positive MNS score . 1 . Any cause Peripheral Neuropathy 2 . Known Spinal Stenosis 3 . Previous Back Injury 4 . Comorbid issue exacerbate CHF 5 . Exacerbation COPD 6 . Chronic steroid use 7 . Underlying connective tissue disease 8 . Previous trauma underlying fracture 9 . Current injury trauma 10 . Skin ulceration 11 . ABPI TBPI measurement measure patient open ulceration sign infection wound weep serous purulent fluid , anywhere foot low extremity 12 . Negative MNS 13 . Previous amputation portion foot 14 . Amputation digit digit consider exclusion criterion 15 . Previous arterial bypass graft 16 . Known cardiac arrhythmia 17 . HG A1C 9.1 % 18 . Uncontrolled fast blood sugar , Type 1 Diabetes . 19 . If antiepileptic antidepressant medication 20 . If patient change pain antiinflammatory medication anytime within past 30 day . 21 . Pregnancy plan pregnancy ( If patient begin research study know pregnant become pregnant study , drop study ) ( Reasoning : evidence use HealthLight therapy pregnant individual . ) 22 . Active osteomyelitis positive osteomyelitis within past six month 23 . Open ulceration sign symptom active infection . 24 . Known Peripheral Arterial Disease ( PAD ) 25 . Previous Lumbar surgery Lumbar Disc intervention anytime within past year</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>